Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Drug Clinical Trial Institution, Guangxi Medical University Cancer Hospital, Nanning, China.
Mol Carcinog. 2023 Sep;62(9):1378-1387. doi: 10.1002/mc.23583. Epub 2023 Jun 6.
Hepatocellular carcinoma (HCC) ranks the third leading cause of cancer deaths with a dismal 5-year survival rate. The mitogen-activated protein kinase (MAPK) signaling pathway is abnormally activated in HCC to promote growth and aggressive metastatic potential of cancer cells. Therefore, genetic variants in the MAPK signaling pathway may serve as potential predictors of Hepatitis B virus (HBV)-related HCC survival. In the present study, we performed a two-stage survival analysis to evaluate the associations between 10,912 single nucleotide polymorphisms (SNPs) in 79 MAPK signaling pathway genes and the overall survival (OS) of 866 HBV-related HCC patients, followed by functional annotation. In combined datasets, we identified two novel and potential functional SNPs (RPS6KA4 rs600377 T>G and MAP2K5 rs17300363 A>C) as prognostic factors for HBV-related HCC, with adjusted allelic hazards ratios of 1.24 (95% confidence interval [CI] = 1.05-1.46, p = 0.010) and 1.48 (1.15-1.91, p = 0.001), respectively. Furthermore, their combined risk genotypes also predicted a poor survival in a dose-response manner in the combined data set (P < 0.001). Additional functional analysis showed that RPS6KA4 rs600377 G and MAP2K5 rs17300363 C alleles were associated with elevated mRNA expression levels of the corresponding genes in normal tissues. These results provide new insights into the role of genetic variants in the MAPK signaling pathway genes in HBV-related HCC survival.
肝细胞癌(HCC)是癌症死亡的第三大主要原因,其 5 年生存率非常低。在 HCC 中,丝裂原活化蛋白激酶(MAPK)信号通路异常激活,促进癌细胞的生长和侵袭转移潜能。因此,MAPK 信号通路中的遗传变异可能是乙型肝炎病毒(HBV)相关 HCC 生存的潜在预测因子。在本研究中,我们进行了两阶段生存分析,以评估 79 个 MAPK 信号通路基因中的 10912 个单核苷酸多态性(SNP)与 866 例 HBV 相关 HCC 患者总生存(OS)之间的关系,并进行了功能注释。在联合数据集,我们确定了两个新的潜在功能 SNP(RPS6KA4 rs600377 T>G 和 MAP2K5 rs17300363 A>C)作为 HBV 相关 HCC 的预后因素,调整后的等位基因风险比分别为 1.24(95%置信区间 [CI] = 1.05-1.46,p = 0.010)和 1.48(1.15-1.91,p = 0.001)。此外,它们的联合风险基因型也以剂量反应的方式在联合数据集中预测了较差的生存(P < 0.001)。额外的功能分析表明,RPS6KA4 rs600377 G 和 MAP2K5 rs17300363 C 等位基因与正常组织中相应基因的 mRNA 表达水平升高相关。这些结果为 MAPK 信号通路基因中的遗传变异在 HBV 相关 HCC 生存中的作用提供了新的见解。